■本研究旨在研究脂质的动力学以及TAF对CHB患者中包括脂肪肝疾病在内的患者脂质分布的影响。
■TC的数据,LDL-c,HDL-c,TG,在基线时收集TC/HDL比值,24周,48周,72周,96周CHB患者在基线脂肪肝进一步分析在一个亚组。
■本研究共招募了137名用TAF治疗的CHB患者。在TAF治疗的96周期间,TC没有显著变化,LDL-c,HDL-c,和TG水平(P>0.05)。TC/HDL-c比值升高,无明显变化(+0.24,P>0.05)。在CHB患者的脂肪肝(n=48),TC,LDL-c,TAF治疗期间TC/HDL-c比值逐渐升高,TG水平在48周时升高至146.63mg/dL(P=0.057),然后下降,但96周时与基线水平相比仍无明显变化(P>0.05)。
■TAF治疗在96周的过程中对CHB患者的血脂状况影响较低,即使在脂肪肝患者中也是安全的。
■[https://www.chictr.org.cn/showproj.html?proj=65123],标识符[ChiCTR2000041005]。
UNASSIGNED: This study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.
UNASSIGNED: The data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.
UNASSIGNED: A total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level (P > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, P > 0.05). In CHB patients with fatty liver (n = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks (P = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks (P > 0.05).
UNASSIGNED: TAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver.
UNASSIGNED: [https://www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].